Increased risk of ectopic pregnancy & congenital malformations. Closely monitor patients & perform ultrasonographic assessments of follicular development prior to & at regular intervals during treatment for risk of OHSS development. Ovarian torsion; multi-fetal gestation & birth; benign & malignant ovarian & other reproductive system neoplasms. Personal or family history of thromboembolic events, severe obesity or thrombophilia. Assess couple's infertility & women's hypothyroidism, adrenocortical insufficiency, hyperprolactinemia, pituitary or hypothalamic tumors & medical conditions contraindicating pregnancy prior to treatment. Additional inj should not be given w/in same treatment cycle; after administration, no additional FSH-containing product should be given prior to stimulation day 8. Not recommended in combination w/ GnRH agonist. May affect ability to drive & use machines. Not recommended in renal insufficiency. Not to be used during pregnancy. Not indicated during lactation.